Key Financial Figures - Quarter Ended September 30, 2026

  • Revenue from operations: ₹11,704,253 (362% increase from ₹2,530,870 in Q2 FY26)
  • Other income: ₹2,248,056 (includes ₹2.32 crore debt write-back)
  • Total income: ₹13,952,309
  • Total expenses: ₹13,779,349
  • Profit before tax: ₹172,961 (compared to loss of ₹2,078,366 in Q2 FY25)
  • Net profit: ₹172,961 (compared to loss of ₹2,078,366 in Q2 FY25)
  • Basic EPS: ₹0.25 (compared to -₹5.56 in Q2 FY25)
  • Paid-up equity share capital: ₹68,788,860 (face value ₹10)

Key Financial Figures - Half Year Ended September 30, 2026

  • Revenue from operations: ₹19,925,205
  • Other income: ₹4,327,186
  • Total income: ₹24,252,391
  • Total expenses: ₹21,879,938
  • Profit before tax: ₹2,372,453 (compared to loss of ₹2,842,863 in H1 FY26)
  • Net profit: ₹2,372,453 (compared to loss of ₹2,842,863 in H1 FY26)
  • Basic EPS: ₹3.45 (compared to -₹7.60 in H1 FY26)

Balance Sheet Position as at September 30, 2026

  • Total assets: ₹380,533,970 (increase from ₹280,532,810 as at March 31, 2026)
  • Property, plant and equipment: ₹109,068,520
  • Inventories: ₹48,121,590
  • Trade receivables: ₹115,073,120
  • Cash and cash equivalents: ₹70,856,790
  • Total equity: ₹93,676,450 (improved from negative ₹61,477,520)
  • Equity share capital: ₹81,250,220
  • Other equity: ₹12,426,230
  • Borrowings: ₹110,283,820
  • Trade payables: ₹169,017,120

Cash Flow Statement - Half Year Ended September 30, 2026

  • Net cash from operating activities: -₹46,481,830
  • Net cash used in investing activities: -₹39,413,600
  • Net cash from financing activities: ₹150,255,380
  • Net increase in cash: ₹64,359,950
  • Cash at beginning: ₹6,496,840
  • Cash at end: ₹70,856,790

Significant Notes and Events

1. The Board meeting was held on November 16, 2026, from 17:30 to 18:00 IST, approving the results.

2. The company operates in a single pharmaceutical segment.

3. During H1 FY26, the company did not charge depreciation on clean room plant and effluent treatment plant.

4. A fire incident occurred at the manufacturing facility on September 28, 2026, damaging plant machinery, finished, and semi-finished material. Management estimates loss of approximately ₹6 crore. No effect has been given in the financial statements as the insurance claim of ₹4.75 crore is pending survey and acceptance.

5. The company wrote back debt of ₹2.32 crore based on representations from creditors, credited to other income.

6. The Board approved allotment of 3,137,586 equity shares of ₹10 at ₹36.50 and 2,145,145 convertible warrants at ₹36.50 (paid-up ₹9.125) on August 29, 2026.

Auditor's Limited Review Report

B A Shah S R Mehta & Co. conducted a limited review and issued an unmodified conclusion with emphasis of matter on:

  • Write-back of long-outstanding related party balances aggregating ₹2.24 crore (₹1.87 crore payable for capital goods, ₹0.07 crore loan from Malwin Pharma Pvt. Ltd., and ₹0.29 crore unsecured loan from Director Mr. Umang A. Gosalia)
  • Fire accident with estimated damage of ₹6 crore and insurance intimation of ₹4.75 crore, with no claim recognized pending survey
  • Non-provision of depreciation on Effluent Treatment Plant due to non-usage during the period